J&J Q3 EPS Craters to $0.09 on $5.5B Talc Charge; Sales Up 5.9%
JNJ sits 40% above its 52-week low of $184.66.
Summary
J&J's Q3 profit collapsed to $0.09 a share on a $5.5B talc settlement charge, but sales grew 5.9% to $25.4B and the underlying franchises — oncology, neuroscience, TREMFYA — are expanding fast enough to offset STELARA's biosimilar-driven decline.
Key Events · Earnings and Guidance · JNJ
-
Q3 Profit Hit by $5.5B Talc Charge
Net earnings fell to $210M ($0.09/share) from $5,152M ($2.12) a year ago; the entire decline reflects the $5.5B accrual for the proposed ovarian cancer talc settlement.
-
Sales Grew 5.9% to $25.4B
Operational growth of 6.0%; oncology rose 16.4% (DARZALEX +15.4%, CARVYKTI +35.5%) and neuroscience 17.3%, while STELARA fell 54.4% to $716M on biosimilar competition.
-
Talc Reserve Now ~$9.0B
Present value of the talc reserve is ~$9.0B, about half current; the ovarian settlement requires participation of at least 95% of remaining claims and does not cover the mesothelioma docket (~76,500 plaintiffs total).
-
Nine-Month Cash Flow $18.9B
Operating cash flow of $18.9B funded $9.6B of dividends and $6.0B of buybacks; cash stood at $16.9B against $44.6B of debt, a $27.4B net debt position.
Analysis · JNJ · Life Sciences
The headline number looks catastrophic — quarterly net earnings of $210M, or $0.09 a share, versus $2.12 a year ago — but the entire gap is the $5.5 billion accrual for the proposed ovarian cancer talc settlement booked this quarter. Strip that out and the underlying business grew: sales rose 5.9% to $25.4B, with oncology up 16.4% and neuroscience up 17.3%. The real story is the talc overhang finally getting a price tag. The reserve now stands at roughly $9.0B present value, about half of it current, and the deal is conditioned on 95% of remaining claimants opting in — so the cash outflow is large, but the legal uncertainty is narrowing. Against that, STELARA's 54% collapse under biosimilar pressure is the structural drag investors have been bracing for, and it is being offset by TREMFYA's 68% growth. Nine-month operating cash flow of $18.9B comfortably funds the $9.6B of dividends paid year to date.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JNJ was trading at $257.78 on NYSE in the Life Sciences sector, with a market capitalization of approximately $621.2B. The 52-week trading range was $184.66 to $281.07. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.